Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

NCT02185690 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02185690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02185690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Completed
Start date
March 7, 2017
Completion date
July 4, 2019
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lungcancer